Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- December31 2003
- Volume 10
- Issue 24
Continued $truggles?
Advertisement
Physician's Money Digest
There are many surveys out and about indicating what physicians earn each year. Too many, some doctors say. Here's another. According to the American Medical Group Association (www.amga.org), below is the 2002 median annual compensation for the specialties of various readers:
Articles in this issue
about 18 years ago
Remain Flexible in the Face of Layoffsabout 18 years ago
Relax, Doc, and Step Back from the Edgeabout 18 years ago
Tread Carefully when Encountering 529sabout 18 years ago
Witness Large Changes at the Big Boardabout 18 years ago
Unfold Mutual Funds' Mountain of Abusesabout 18 years ago
New Mutual Funds Gain Growing Approvalabout 18 years ago
Close-Up: 412(i) Planabout 18 years ago
Investors Take a Cue from Institutionsabout 18 years ago
Doc's Stocks #10 Current Standingsabout 18 years ago
Find Reliable Asset Protection OverseasAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5